Page 109 - SGH PR REPORT - FEBRUARY 2025

2/19/25, 11:55 AM Latest News
and accurately detect a wide range of pathogens, including those that are difficult to culture, dramatically
improving diagnostic accuracy and speed. By identifying the specific microorganisms responsible for

infections, MALDI-TOF ensures the selection of the most effective antibiotics, mitigating the overuse of
broad-spectrum antibiotics and combating antibiotic resistance.

This partnership is expected to benefit more than 2 million patients annually, allowing the healthcare provider
to deliver quicker, more accurate diagnostics and enhance patient outcomes. The agreement aims to

streamline microbiology diagnostic processes, reducing turnaround times and ensuring timely treatment for
patients. With faster and more precise diagnoses, the collaboration is set to elevate the overall healthcare

experience, providing significant advantages to both patients and healthcare providers.
Philippe Villard, Senior Director of Commercial Operations, EMEA at BD Company, stated: “We are excited to
collaborate with Saudi German Health on this innovative initiative. The rollout of our advanced diagnostic

solutions will significantly benefit healthcare providers by improving diagnostic accuracy and efficiency.
Technologies like MALDI-TOF have demonstrated their effectiveness in enhancing diagnostic outcomes in

other regions, and we believe this collaboration will yield similar results in the Kingdom of Saudi Arabia.”
The rapid diagnostic solutions introduced by BD and SGH are expected to become a model for healthcare
providers across the region. This partnership will usher in an era of faster, more accurate diagnoses and

improved patient care by refining diagnostic accuracy and streamlining processes. This partnership will
significantly enhance the social and economic value of the local healthcare system, contributing to the overall

well-being of the community.
-Ends-

https://www.arabbnews.com/english/Latest-News.asp?id=18123 2/2